We are live on ! Find out more
QTTB icon

Q32 Bio

120 hedge funds and large institutions have $123M invested in Q32 Bio in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more call options, than puts

Call options by funds: $793K | Put options by funds: $369K

37% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 30

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

1% more funds holding

Funds holding: 119120 (+1)

0.17% more ownership

Funds ownership: 3.12%3.29% (+0.17%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

51% less capital invested

Capital invested by funds: $252M → $123M (-$129M)

Holders
120
Holders Change
+1
Holders Change %
+0.84%
% of All Funds
1.85%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
20
Increased
41
Reduced
30
Closed
18
Calls
$793K
Puts
$369K
Net Calls
+$424K
Net Calls Change
-$130K

QTTB Hedge Fund Activity: Q4 2021 in Review

120 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q4 2021, worth a combined $123M — down 51% from $252M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new QTTB positions and 18 closed out — a net gain of 2 holders — while 41 added to existing stakes and 30 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $5.21M. The largest seller was JP Morgan Chase, cutting an estimated $1.99M.

  • 120 institutional investors held Q32 Bio (QTTB) as of Q4 2021, up from 119 in Q3 2021.
  • Funds reported $123M of Q32 Bio stock for Q4 2021, down 51% quarter-over-quarter.
  • 20 funds opened new Q32 Bio positions in Q4 2021 and 18 closed out, a net change of +2 holders.
  • The largest Q32 Bio buyer in Q4 2021 was Woodline Partners, an estimated $5.21M added.
  • The largest Q32 Bio seller in Q4 2021 was JP Morgan Chase, an estimated $1.99M sold.

Based on aggregated 13F filings for Q4 2021.